| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Clinical and Vaccine Immunology, May 2008, p. 888-890, Vol. 15, No. 5
1071-412X/08/$08.00+0 doi:10.1128/CVI.00453-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland,1 Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland,2 National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland,3 Department of Laboratory Medicine, University of Washington, Seattle, Washington,4 Institute of Public Health, Makerere University, Kampala, Uganda,5 Department of Population, Family and Reproductive Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland6
Received 29 October 2007/ Returned for modification 28 January 2008/ Accepted 21 February 2008
Ugandan subjects (820) were tested by Focus HerpeSelect enzyme-linked immunosorbent assay (ELISA), Kalon herpes simplex virus type 2 ELISA, and BioKit rapid test, and the results were compared to those of Western blotting. Higher-than-standard-index cutoff values gave optimal sensitivity and specificity. Kalon ELISA was the optimal assay when an index value of 1.5 was used (sensitivity, 91.7%; specificity, 92.4%).
Published ahead of print on 5 March 2008.
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |